Podcasts about blood tests

What if you could test your cancer cells BEFORE choosing a treatment and actually watch which drugs kill them? That's not science fiction. That's what we did for Kamren — a 38-year-old man in my own family who was diagnosed with a rare, complex cancer that conventional medicine struggled to classify, let alone treat. In this episode, I'm pulling back the curtain on three precision tests that most oncologists have never ordered and explaining exactly what they revealed, what they changed, and why they matter for every cancer patient, not just his. We're talking about:

Send Zorba a message!Zorba gives an update on the new Alzheimer's blood test developments from the Mayo Clinic and other institutions. And he poses the question: Would you want to know?Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba gives an update on the new Alzheimer's blood test developments from the Mayo Clinic and other institutions. And he poses the question: Would you want to know?Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

A blood test may predict the start of Alzheimer's symptoms years in advance and doctors say it could become a game changer. The study shows a blood test can help identify healthy people at high risk for Alzheimer's disease and how far their disease has progressed.

New research suggests a future where primary care physicians could use a highly accurate blood test to help diagnose—or rule out—Alzheimer's in people experiencing memory and thinking problems. We spoke with Kristen Cusato of Alzheimer's Association (Northeast chapter.)For more information: https://www.alz.org/ct

Doctors say a new blood test could help predict the onset of Alzheimer's disease years before symptoms appear. The test measures a biomarker known as p-tau217, which researchers say can detect signs of the disease five to ten years before otherwise healthy people begin showing symptoms. Experts believe the breakthrough could transform how Alzheimer's is diagnosed and monitored.

Researchers at Toronto's Princess Margaret Cancer Centre have launched a major study to see if a simple blood test can detect microscopic traces of cancer left behind after treatment. If successful, it could allow doctors to identify a cancer recurrence long before it appears on a scan. To talk about this potential breakthrough, Tamara is joined by Dr. Lillian Siu, medical oncologist at Princess Margaret Cancer Centre, Professor of Medicine at the University of Toronto, and Scientific Lead of the Peter Gilgan Centre for Early Cancer Detection Research.

AP correspondent Donna Warder reports on a new blood test that could determine whether someone will develop Alzheimer's disease.

Your patient brushes well, avoids sweets — and still keeps getting decay. What if the answer isn't in their mouth at all? What if two inexpensive finger-prick tests told you more about a patient's gum disease and implant prognosis than anything on the radiograph? And here's the uncomfortable one: if the science is this clear, is not checking starting to look like a medico-legal risk? Especially for imlpant surgery! This is a conversation with Dr Tif Qureshi — the dentist who changed how the profession thinks about the lifelong patient, the envelope of function, and Align, Bleach, Bond. He's gone down a new rabbit hole: metabolic health. In general practice he's now doing blood tests — HbA1c and vitamin D — and making the case that the mouth isn't connected to the body, it is the body. This isn't about becoming a “biological dentist” (as you'll hear, Tif is refreshingly blunt about the wilder end of that world). It's about respecting the biology, screening sensibly, and helping patients where we're genuinely placed to help. https://youtu.be/mt1MXLFCTp0 Watch PDP275 on YouTube Protrusive Dental Pearl: Test Yourself First Before you even think about introducing blood tests for your patients, ask whether you're checking your own biomarkers at a sensible interval. The deepest way to understand this topic is to learn it on yourself and your family first — run your own HbA1c, vitamin D, iron, and liver and kidney markers, and see what the data tells you. Start quarterly, like hygienist visits, then stretch to six-monthly or annual once things look good. Getting invested in your own numbers is what makes better food and lifestyle choices actually stick — and it's the honest starting point for ever offering this to a patient. What You'll Take From This Episode The metabolic lens — why one disordered glucose-and-insulin system sits under so much chronic and dental disease, and why dentistry is well placed to act on it. Sugar, redefined — why patients who avoid sweets still get decay, and how frequency of starchy carbs drives the problem. The two biomarkers that matter most — what HbA1c and vitamin D each tell you about caries, perio and healing. How to run it in practice — finger-prick logistics, what to test, and how to raise it on the medical history form. The medico-legal case — why documenting these markers can protect you before implant, graft and perio work. Highlights of This Episode 00:00  Why Dentists Should Care About Blood Tests 06:00  Metabolic Disease: The Root Cause Dentists Miss 13:00  Why Starchy Carbs Cause Decay, Not Just Sugar 15:50  HbA1c and Caries: What the SHIP Study Shows 21:00  Insulin Resistance: The Hidden Driver of Gum Disease 26:00  How to Talk to Patients About Diet Without Scaring Them 31:00  Why Vitamin D Deserves a Place in Dentistry 34:00  Vitamin D, Implant Failure and Perio Risk 37:00  Blood Tests as Medico-Legal Defence 42:00  What Dentists Should Test: HbA1c and Vitamin D 44:00  How In-Practice Blood Testing Actually Works 50:00  The Mouth Is the Body: Screening, Not Diagnosing 51:00  Is This Biological Dentistry? An Honest Answer 57:00  How to Learn Blood Testing for Your Practice From the Guest Dr Tif Qureshi qualified from King's College London in 1992 and is a Past President of the British Academy of Cosmetic Dentistry. He is Founder and Clinical Director of IAS Academy, best known for pioneering Align, Bleach, Bond and Progressive Smile Design, and as a teacher of the Dahl concept. His current focus is metabolic health in general practice.

Scientists at the Princess Margaret Cancer Centre are using an emerging blood test technology to look for small traces of cancer in a patient's bloodstream. It will make it easier and faster to detect recurring cancer in its earliest stages but more research needs to be done before it can be used confidently or on people without cancer. Guest host Piya Chattopadhyay speaks with Dr. Lillian Siu is a senior scientist at UHN's Princess Margaret Cancer Centre and a scientific lead at the Peter Gilgan Centre for Early Cancer Detection Research about the potential of this breakthrough research.

Send us Fan MailA Gluten Free Podcast Episode 244 My guest on today's episode is Associate Professor, gastroenterologist and world-leading coeliac disease researcher, Jason Tye-Din. We'll talk about the latest updates on the Interleukin 2 blood test, updated advice around oats as part of a gluten free diet and all the other incredible research he and his team at WEHI are currently undertaking. What we'll cover: * Introducing Jason and our previous episode together * How coeliac disease is a systemic autoimmune disease that affects all parts and organs of the body * How the Interleukin 2 diagnostic tool works * Interleukin 2 blood test being used in various other coeliac disease research trials * Interleukin 2 blood test used in the Gluten Threshold Study to determine if T cells are being activated when participants are ingesting very low levels of gluten * Interleukin 2 (IL-2) blood test soon to be used in a trial involving children * Updates around this blood test and implementation plans * Non-biospy approach in diagnosing coeliac disease and how IL-2 could play a part in this * Working on a salivary coeliac disease test * How the IL-2 test might work in people with potential coeliac disease * Gluten Threshold Study and how IL-2 was used in the study * The response from the Gluten Threshold Study * World Health Organisation reference threshold for gluten and possibility to clear up confusion around ‘may contain gluten' statements * Defining an action level in a standard serve of food * Jason's advice on enzymes that claim to break down small amounts of gluten * Importance of not using symptoms as a measure of being glutened or not * Possible adjunct management drugs and other therapeutics other than a strict gluten free diet for people with coeliac disease* Advice for oats as part of a gluten free diet for Australian adults and children living with coeliac disease * ENDIA (Environmental Determinants of Islet Autoimmunity Study) updates * Eotaxin and brain fog coeliac disease study * Pros and cons around population screening of coeliac disease * NSW school children being tested for coeliac disease and Type 1 diabetes * International Celiac Disease Symposium 2026 in Melbourne Links Contact the nurses to be involved in WEHI studies - coeliac@wehi.edu.au Professor Jason Tye-Din's previous podcast appearanceSuitability of Oats as part of a gluten free diet for Australians living with coeliac disease ENDIA study https://www.icds2026.org/ Coeliac Disease Research LabJoin A Gluten Free Podcast Facebook Group 

People with a history of tobacco smoking are recommended to have screening CT for lung cancer, but many of them choose not to be screened. A new study looks at the ability of a blood test to discern who is … Can a blood test improve lung cancer screening? Elizabeth Tracey reports Read More »

When someone has a years-long, multiple pack history of smoking, they are recommended to undergo screening for lung cancer utilizing a technology known as low dose computed tomography or low dose CT. Yet only about 18% of those eligible for … Will a blood test compel more people to be screened for lung cancer? Elizabeth Tracey reports Read More »

More and more blood tests to screen for cancer are coming on the market, with a new one looking at proteins in the blood helping identify who is at risk to develop lung cancer. Kimmel Cancer Center director William Nelson … How often can a blood test predict cancer risk? Elizabeth Tracey reports Read More »

U.S. President Donald Trump says the ceasefire between Iran and the U.S. is over. Both countries are trading fire again, in the worst clashes since the two countries signed an agreement to stop fighting last month.And: For cancer survivors, the lingering fear of recurrence never truly fades. A new technology is helping find the tiniest traces of cancer using basic blood work.Also: Weeks after tens of thousands of lives were shattered by the earthquakes that rocked Venezuela, the country's children face a fragile new reality. CBC is in Venezuela.Plus: Researchers get a look at Shackleton's last ship — the Quest, more details on charter boat tragedy in B.C., the heat is back in Western Europe, and more.

When large populations of people were screened for multiple cancers using a blood test, not only didn't cancers get found earlier, others who were not screened had delays in their diagnosis and treatment of cancer. Johns Hopkins Kimmel Cancer Center … Should blood tests to screen for cancer be used on a population basis? Elizabeth Tracey reports Read More »

A blood test capable of detecting multiple cancers seems like a dream come true, yet a new study looking at such a test used in populations of people failed to find cancers earlier, and also delayed diagnosis for others. William … Just how expensive could it be to screen populations of people for cancer using blood tests? Elizabeth Tracey reports Read More »

The tumor microenvironment (TME), composed of immune cells, fibroblasts, and endothelial cells, has emerged as critical to pathogenesis, prognosis and treatment for cancer (schematic Figure below). There's no such thing as TMI (too much information) for TME! Yet there's still no way of assessing it in the clinic by a blood test, and even by invasive biopsy the sampling bias for TME without broader geographic context can lead to important mistakes. That isn't used for clinical decision making. The TME field is about to change.Recently, Professor Aaron Newman at Stanford and colleagues from many US leading centers published a landmark paper in Nature. It may ultimately be considered one of the most important leaps in cancer diagnostics in decades. Ground Truths is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.This was a massive undertaking involving 10 million single-cell RNAseq in 10 types of cancer to define 9 TME types by spatial omics which they called “spatial ecotypes”. It was AI-enabled by machine learning (Spatial Ecotyper from biopsy samples) and extrapolating that to knowledge to deep learning AI (Liquid Ecotyper from blood samples). The whole project took several years.Here's an infographic summary I made with the help of NotebookLM along with the Figures that follow.Some of the key points from our conversation:—TME is the soil in which the cancer cells live. It strongly influences whether the cancer cells will thrive or not, spread, respond to therapy, and determine the fate pf pre-cancerous lesion (as seen in recent important paper in pancreatic cancer evolution and colon cancer development).—Ecotypes, a term coined in 1922, to get at the local environment of tissue and cancer, was repurposed in this new project. Good metaphor: neighborhoods. And emphasis on location , location, location like real estate.—In the clinic today, the only window to TME is via a biopsy. But decisions for treatment are not based on TME, they are based on biomarkers like tumor mutation burden (TMB), PD-L1 levels , or volume of tumor DNA by liquid biopsy.—TME is dynamic and changes over time so a single snapshot won't cut it. —Spatial 3D maps of TME from 10 million cells, 10 cancer types led to 9 spatial ecotypes (with the Spatial Ecotyper machine learning). Validation across 3D grids (such as Visium) and multiple cohorts. The cell location base within TME is striking. —These 9 neighborhoods are conserved and very different. SE4-immune system is asleep, hypoxic; SE 7/8 are “war zones” rich with immune cells, hot tumor; SE 5 exhibits intense immunosuppression, hostile vs immune system, portends poor survival, SE9 deep in core, driving angiogenesis (new blood vessels)—Now rich information from these 9 SEs needs to be extrapolated to a holistic blood test of TME. It turns out an extension of tapping into methylation as used by some liquid biopsy cell-free DNA tests works very well, providing cell identity from the DNA fragments leaked into the blood. To get to TME spatial biology in a tube of blood. Akin to wastewater surveillance form municipals for detection of infectious disease pathogen sequence variants and circulating levels. A triumph of AI analytics made this possible!—The Liquid Ecotyper was validated in 78 patients with malignant melanoma pre-treatment from Yale University. SE 7/8 benefited from immune checkpoint therapy; SE4 resisted treatment, shorter survival. Matched with tissue biopsy work. —Work beyond publication ongoing in many types of lung cancer, bladder cancer, mesothelioma, and response to other therapies like CAR T and bispecific antibodies. This is critical since we have slew of different cancer immunotherapies (see my pyramid Ground Truths review) and we're not sure who, when, how to use them to drive optimal cancer outcomes in patients. May also help predict other types of therapy (not just immunotherapy) for cancer.—The blood test can performed serially which is a major advance compared with how we are currently “flying blind” and misled by imaging. —Started a company Liquid Cell Dx to make the TME blood test commercially available. May be available sooner in the academic centers in the current study.—The use of SEs may extend beyond cancer!A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you're not a subscriber, please join!If you found this interesting PLEASE share it!Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 51 summer interns coming in 2026! These are high school, college and medical students selected from thousands of applicants. We couldn't do this expanded program without the funds coming in through Ground Truths.Thank you Dr Poonam Desai, Harshi Peiris, Ph.D., YOUR DOCTOR KLOVER, KL, Jessica Coffman, and >400 others for tuning into my live video with Aaron Newman! Join me for my next live video in the app. Get full access to Ground Truths at erictopol.substack.com/subscribe

JAMA Medical News Associate Managing Editor Kate Schweitzer and Lead Senior Staff Writer Rita Rubin discuss "First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds." Related Content: First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds

Send us Fan MailA treasure map? On Dynasty? We had to pause, rewind, and make sure we heard that right. We're recapping Dynasty Season 5 Episode 11 “Swept Away” on Soap Lore, and the show swings from hotel-room secrets to jungle-mystery logic in record time. Jeff Colby realizes his latest fling is Nikki Defilibuster, widow of Peter Defilibuster, and what starts as a scandal quickly turns into a full-on treasure hunt setup with a “solid gold Dinka entity” and two halves of a map. The twist that really matters: Fallon Carrington might not have been on that plane at all. So where is she, and who's holding the missing piece?  We also dig into the quieter tension that's been building for a while. Steven and Claudia feel like they're being nudged apart, and Luke's Santa Barbara “work trip” details raise eyebrows even when the chemistry is still finding its footing. On the Carrington power front, Blake and Crystal are still reeling after baby Christina's health scare, and Crystal's gut tells her the official story around Ahmed's death does not add up, especially once Dominique and Adam help Blake spin a press conference that one skeptical reporter refuses to swallow.  Then Alexis does what Alexis does best: control the board. A threatened paternity blood test pushes her into escape mode, a blizzard strands Dex and Amanda in a luxury cabin, and the morning after is pure awkward fallout. Just when it can't get messier, Alexis shows up with champagne and a London plan that rewrites everyone's next move. Listen now, then subscribe, share the episode with a fellow soap fan, and leave us a review. What's your theory on Fallon and the treasure map?

Blood tests and other biomarkers are bringing researchers closer to detecting Alzheimer's disease before memory loss begins — a shift that could reshape prevention, treatment, and the way families think about risk.Dr. Joshua Grill, director of the UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND) and UCI's NIA-funded Alzheimer's Disease Research Center, explains how advances in amyloid PET scans, spinal fluid testing, and blood-based biomarkers are changing Alzheimer's research and care. Grill has published more than 150 articles and is nationally recognized for his work on clinical trials, recruitment and retention, and biomarker disclosure.In this conversation with Being Patient's Mark Niu, Grill discussed why these tests are useful today for people already experiencing cognitive symptoms, why they are not yet recommended as a routine risk test for people without memory problems, and how biomarkers are helping researchers design prevention trials for people at higher biological risk. He also explained the emotional, ethical, and legal questions that come with assessing Alzheimer's risk and what still needs to happen before early testing and treatment become part of routine care.---If you loved listening to this interview, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://beingpatient.com/live-talks/

This week on the goodsugar Podcast, Ralph Sutton sits down with Natalie Sampson, board-certified genetic counselor, integrative health expert, and founder of Golden Genetics Health, to separate science from hype when it comes to genetic testing.They dive into how your genes influence disease risk, supplements, medication response, inflammation, Alzheimer's, histamine intolerance, and even which workouts and nutrition strategies may work best for your body.Natalie also explains why most online DNA tests aren't telling you the full story, how personalized medicine is changing healthcare, and why genetics should empower, not scare, you.Whether you're curious about longevity, preventative health, or optimizing your wellness, this episode is packed with practical insights.00:00 Introduction00:41 Meet Genetic Counselor Natalie Sampson02:12 How Natalie Got Into Genetics03:54 Family Health & Autoimmune Disease Journey05:13 Nature vs. Nurture Explained08:23 What Genetic Tests Actually Show09:58 Chris Hemsworth & Alzheimer's Risk11:07 Can Saunas Reduce Alzheimer's Risk?12:00 Personalized Supplements vs. Trends13:21 Histamine Intolerance & Hidden Causes14:02 How Genetics Predict Medication Response15:15 Why Doctors Are Finally Embracing Genetics17:05 What Golden Genetics Health Does18:05 How Much Does Genetic Testing Cost?18:55 Blood Test vs. Saliva DNA Testing19:37 Why DNA Tests Are Different From Blood Work20:22 Is It Better NOT to Know Your Genetic Risks?21:43 Best Supplements for Most People22:45 Genetics Success Stories23:11 Biggest Misconceptions About Genetic Testing24:14 How to Avoid Bad Genetic Testing Companies25:10 Is 23andMe Accurate?25:54 Natalie's Celiac Disease Diagnosis27:09 Hidden Gluten & Surprising Triggers28:03 Why Some People Tolerate Gluten Better in Europe28:27 Where to Learn More About Golden Genetics Health29:03 Podcast Discount for Genetic Testing29:21 OutroFollow Natalie Sampson:

Send us Fan MailFor decades, oncologists have had to wait until cancer became visible on a scan before knowing whether it had returned. But what if doctors could detect microscopic traces of cancer months earlier with a simple blood draw - and use that information to decide who actually needs treatment? Today we're exploring a breakthrough that may fundamentally change the way cancer is monitored and treated.Eric Matthews is General Manager of Biopharma at Natera ( https://www.natera.com/ ), a leader in personalized molecular diagnostics and the company behind Signatera, the first FDA-approved molecular residual disease companion diagnostic.Over the past 25 years, Eric has helped bring nine medicines to market across nineteen indication launches, building a career at the forefront of oncology, precision medicine, and biopharmaceutical innovation.Before joining Natera, Eric served as Chief Business Officer at Caris Life Sciences, where he focused on diagnostic, data, and drug discovery partnerships. Prior to that, he was Chief Commercial Officer at Arcus Biosciences, helping forge major strategic collaborations including Arcus' landmark partnership with Gilead Sciences.Eric's previous leadership roles include Vice President of Global Marketing for Immuno-Oncology at AstraZeneca and commercial leadership positions at Genentech and Roche, where he worked on some of the most influential cancer therapies of the modern era, including Avastin and Tecentriq.Eric holds an MBA in Health Sector Management, a Master's in Health Policy and Economics, and dual bachelor's degrees in Molecular Biology and Economics from Duke University.Today we discuss the future of molecular residual disease testing, how personalized blood-based diagnostics are changing cancer care, the recent FDA approval of Signatera as the first MRD companion diagnostic, and what the next decade may hold for truly individualized oncology.#CancerResearch #CancerDetection #PrecisionMedicine #Oncology #LiquidBiopsy #Signatera #Natera #CancerCare #Biotech #HealthcareInnovation #Immunotherapy #Tecentriq #BladderCancer #MolecularBiology #PersonalizedMedicine #CancerTreatment #MedicalInnovation #FutureOfMedicine #Biotechnology #ProgressPotentialPossibilitiesSupport the show

Three major allergy testing methods—skin prick, blood IgE, and oral food challenges—and how each one helps pinpoint your triggers. Learn when to use which test and why accurate diagnosis matters. WhatAreAllergies.com City: Dallas Address: 3145 Olive Street Website: https://whatareallergies.com

Discover how advanced blood-based assays and multi-modality screening can identify silent cellular changes before they impact your longevity protocol.Traditional cancer screenings are constrained by structural limitations, capturing less than twenty percent of eventual diagnoses due to strict age thresholds, invasive procedures, and systemic healthcare delays. Dr. Tarek Mouhieddine from the Dana-Farber Cancer Institute introduces a comprehensive strategy for multi-cancer early detection that combines circulating tumor biomarkers, DNA methylation profiling, and whole-body MRIs. This multi-layered screening architecture seeks to identify up to fifty cancer subtypes at stage one, where therapeutic interventions achieve the highest cure rates. The discussion details how tracking biomolecular trends through annual blood draws allows for early intervention without the radiation risk of repetitive CT scans or the complications of premature tissue biopsies. Dr. Mouhieddine also emphasizes that maintaining baseline cellular health preserves physiological resilience, directly dictating how well an individual tolerates therapeutic interventions. This framework offers actionable insights for individuals over 50 looking to optimize their preventative diagnostic protocols.

Play The Mighty Challenge, Wednesday June 17 edition to see if you have the answer!

This week, Bobbi Conner talks with MUSC's Dr. Maggie Westfal about a blood test being used to detect the return of colon cancer.

Did you know a small sample of hair can reveal what three months of blood tests might miss? In episode 204, I'm sitting down with Dee Davidson, board-certified functional health practitioner and hormone health expert, to talk about the HTMA hair mineral test and why it's one of the most useful tools she uses with her clients. If you have Hashimoto's and you feel like something is still off despite normal labs, this episode is for you. In this episode, you'll learn: Why a blood test gives you a real-time snapshot but the HTMA shows your mineral reserves over three full months What the hair test actually measures, including fight-or-flight status, blood sugar patterns, adrenal load, and hidden stressors How to stop guessing at supplements and start understanding what your body actually needs Hit play and find out what your minerals have been trying to tell you.   CONNECT WITH DEE DAVIDSON Website: confidentlyloveyourself.com  Instagram: @confidently_love_yourself   JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about Find all links on my resource page: https://healthwithhashimotos.com/resources/   ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.

June 10, 2026 ~ Dr. Marina Novikova explains new blood tests that may help predict Alzheimer's disease and what it could mean for early detection. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you are thinking about having a baby in the next year or two, or you have been trying for a while and wondering if your nutrition could be doing more, this episode is a genuinely useful place to start. And if you are in your 20s or 30s and have not had a blood test recently because you feel fine and assume everything is probably okay, Leanne and Susie have something to say about that too. This week on The Nutrition Couch, they dig into the nutrition and lifestyle strategies that actually move the needle on fertility outcomes, what the research says about diet patterns, key nutrients, and male fertility, and the common mistakes that quietly work against conception that most women have never been told about. In this episode: The Australian longitudinal study of over 5,000 women linking anti-inflammatory dietary patterns to better fertility outcomes, and what that actually looks like on a plate day to day The key nutrients that appear time and time again in fertility research: omega-3s, vitamin D, vitamin E, and natural folate, why food sources beat supplements in almost every case, and the one supplement Susie did take during pregnancy The MTHFR gene mutation: what it is, how common it is, why women with this mutation should not be taking synthetic folate in standard prenatal supplements, and how to find out if you have it Why male fertility contributes to 40 to 50% of fertility challenges and is chronically overlooked, and what partners should actually be doing differently The under-eating and overtraining pattern that silently disrupts ovulation and hormonal health even in women who appear to be doing everything right The truth about caffeine and fertility: the research does not say what most people assume, and Susie explains exactly how much is genuinely safe if you are trying to conceive The blood tests Leanne recommends for every woman in her 20s and 30s, including the ones most GPs do not automatically order, and the vague symptoms that are easy to dismiss but might actually signal something easily fixed Why low ferritin is one of the most underdiagnosed and undertreated issues in young Australian women, and Susie's case study of a client whose iron had been dangerously low for two decades without anyone properly addressing it The Harvest Pantry Protein Smoothie reviewed: clean ingredients, impressive packaging, and a protein claim on the front of the pack that requires an asterisk the size of a footnote to actually be true The nine-month-old baby and solids question: how much milk is too much, why iron should be the focus of every meal at this age, and the feeding order that makes a bigger difference than most parents realise Shop Designed by Dietitians: Looking to support your protein, creatine, magnesium, or collagen intake with evidence-based supplements made in Australia? Visit designedbydietitians.com Keep sharing The Nutrition Couch with the women in your life. This is exactly the kind of episode worth passing on.See omnystudio.com/listener for privacy information.

Why do some people appear to age faster than others, even when they are the same age? Researchers increasingly believe that chronological age tells only part of the story. Biological age attempts to capture how well the body's systems are functioning and may provide a more meaningful picture of overall health. A research paper on this topic was published in Volume 18 of Aging titled “Blood biochemical and gut microbiotic neural network models forecasting human biological age.” In the study, Russian researchers explored whether information from routine blood tests and the gut microbiome could be used to estimate biological age. Full blog - https://aging-us.org/2026/06/blood-tests-and-gut-bacteria-may-help-reveal-your-biological-age/ DOI - https://doi.org/10.18632/aging.206360 Corresponding author - Alexey Moskalev - amoskalev@med.ru Abstract video - https://www.youtube.com/watch?v=wg3YEwXMKWY Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206360 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, biological age, blood biochemistry, gut microbiome, neural network To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode of It Takes Balls, testicular cancer survivor Tony Salas shares how his cancer journey led him into one of the newest and most rapidly evolving areas of cancer surveillance: MicroRNA-371 testing and Signatera ctDNA monitoring.Tony opens up about the symptoms and diagnosis that changed his life, including the whirlwind of appointments, surgery, and learning how quickly testicular cancer treatment decisions have to be made. But what makes his story especially unique is what came after treatment—navigating surveillance while trying to avoid chemotherapy and gain greater confidence in whether his cancer was truly gone.Throughout the episode, Tony discusses using MicroRNA 371, an emerging blood test showing major promise in detecting active germ cell tumors, along with Signatera, a personalized circulating tumor DNA (ctDNA) test designed to monitor for residual disease and recurrence. He shares what it was like balancing traditional surveillance methods like CT scans and tumor markers with these newer technologies, and how the uncertainty of recurrence can weigh heavily on survivors mentally and emotionally.The conversation also explores the emotional side of survivorship, including scannxiety, the fear of recurrence, and the challenge of moving forward after treatment while still feeling tied to constant monitoring. Tony speaks candidly about the importance of self-advocacy, staying informed about evolving cancer research, and finding ways to regain a sense of control during survivorship.This episode is not only a powerful survivor story, but also an insightful look at the future of testicular cancer surveillance and personalized cancer monitoring. Whether you're navigating a diagnosis, currently in surveillance, or interested in the latest advances in testicular cancer treatment and recurrence detection, Tony's experience offers both hope and perspective.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyJoin The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsConnect with Tony:https://www.instagram.com/tone_loc17/https://www.facebook.com/coachtony05Follow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.x.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker:https://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

"There is no one magic test for brain health,” says Richard Isaacson, MD.    Isaacson is a Harvard-trained neurologist who directs the Precision Prevention Program at Atria Health and Research Institute and founded the world's first Alzheimer's Prevention Clinic at Weill Cornell Medicine/NewYork-Presbyterian. A leader in precision-medicine approaches to Alzheimer's risk reduction, he has served as principal investigator for multiple research initiatives focused on individualized care. He recently led an NIH-funded clinical trial showing that a free online tool (RetainYourBrain.com) reduced Alzheimer's risk by 16% in six months, and is working to democratize brain health testing through an at-home, lower-cost blood biomarker test (AlzLabs.org). Show notes: 00:00 - What we don't know about Alzheimer's 04:49 - Where to start with Alzheimer's risk 06:55 - Lifestyle first: optimizing what you can control 10:39 - Using wearables & health tech for brain health 16:19 – Why there's no perfect blood test for the brain 29:06 - Cutting through the information noise 31:10 - Steps to take when symptoms appear 35:37 - Is it actually memory loss? 38:54 - The future of Alzheimer's testing Referenced in the episode:  Free cognitive risk & assessment tools: retainyourbrain.com Free information about blood biomarkers: ind.org/bloodtest   Free information about home testing: alzlabs.org We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The American Cancer Society (ACS) recently updated its colorectal cancer screening recommendations, adding new stool-based and blood-based screening options. What's changed in the new American Cancer Society screening recommendations • New stool DNA and stool RNA screening tests • The role of blood-based cancer screening tests • Why colonoscopy remains the gold standard • Why a follow-up colonoscopy is still needed after a positive screening test • Screening recommendations for adults ages 45–75 • The rise in colorectal cancer among younger adults and what patients should know The most important takeaway? Colorectal cancer is highly preventable, and the best screening test is the one that gets completed. This episode is intended for educational purposes only and should not replace medical advice from your healthcare provider.  

Headlines: – Welcome to Mo News + AI Puerto Rico Song Going Viral (02:00) – Iran War: Trump Says Political Pressure Will Not Sway Him in Talks (07:00) – Trump: Middle Eastern Countries 'Owe It to Us' to Join Abraham Accords (10:40) – Israel Issues New Evacuation Warnings For Southern Lebanon  (13:00) – Iran's Internet Is Partially Restored (14:15) – Where In The World Is Missing N.J. Congressman? (15:45) – U.S. To Set Up Quarantine Facility in Kenya for Americans Exposed to Ebola (23:00) – Why Americans Are About to Pay Even More at the Grocery Store (26:50) – DHS Sec. Reveals Plan To Potentially Limit International Travel At Some Major West Coast Airports (29:40) – Experts Just Added A Blood Test To Colon Cancer Screening Options, As Many Skip Colonoscopies (31:50) – Trump Says He May Attend Knicks' NBA Finals Game In New York (34:00) – On This Day In History (38:40) Thanks To Our Sponsors: – ⁠Monarch⁠ - 50% off your first year | Code: MONEWS – ⁠Factor⁠ - 50% off your first box | Code: monews50off – Industrious⁠⁠ - Coworking office. 50% off day pass | Code: MONEWS50 – ⁠LMNT⁠ - Free Sample Pack with any LMNT drink mix or 12oz cans purchase

https://gohealthybefit.com/Discover how to order blood tests online without a doctor's referral or insurance, access over 4,500 walk-in labs nationwide, and get fast, private results at transparent prices. Learn the costs, process, and benefits. FPK Services, LLC City: Houston Address: 11150 S Wilcrest Dr, Suite 100 Website: http://www.stdcheck.com

Of the human body's many organs, the liver is arguably one of the hardest…

Dementia affects millions of people globally, causing profound memory loss and cognitive impairment and compromising the ability to function independently in day-to-day life. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, sat down with Gil Rabinovici, MD, a neurologist and director of the UCSF Alzheimer's Disease Research Center, to discuss the latest developments in dementia and Alzheimer disease research. Related Content: A New Era in Dementia—Advances in Diagnostic Blood Tests, Novel Drugs, and the Power of Lifestyle Changes

Send us Fan MailIn this week's Friday Five, I'm breaking down some of the standard blood markers I commonly look at in clinic when somebody is dealing with autoimmune disease, inflammation, fatigue, or hair loss — including alopecia.One of the biggest misconceptions I see is that “normal” blood tests automatically mean everything is functioning optimally. But in reality, many people continue to struggle with symptoms despite being told their results are fine.In this episode, I explain why interpretation matters just as much as the numbers themselves, and why looking at patterns across the body can often reveal far more than one isolated marker.I discuss:• Ferritin, transferrin and the wider iron picture• Why ferritin alone may not tell the full story in inflammatory conditions• Thyroid markers beyond TSH, including Free T3, Free T4 and thyroid antibodies• The role of thyroid hormone conversion in energy, metabolism and hair health• Vitamin D and immune regulation• Zinc and its role in immune resilience, skin and hair health• White blood cells, neutrophils and lymphocyte patterns in autoimmune disease• What triglycerides can tell us about metabolism, blood sugar regulation and inflammation• Why markers like serum B12 or HbA1c may not always reflect the full picture• The importance of interpreting symptoms alongside laboratory testingThis episode is not about becoming fearful of blood tests or obsessing over numbers. It's about understanding the body more deeply and recognising that subtle shifts in markers can sometimes provide important clues long before symptoms become more significant.If you've ever been told “everything looks normal” but still feel that something is off, this episode is for you.

JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin discuss "These Blood Tests May Detect Dozens of Cancers, but Will They Save Lives?" Related Content: These Blood Tests May Detect Dozens of Cancers, but Will They Save Lives?

Your doctor orders a lipid panel every year — but 3 cheap blood tests predict heart disease, diabetes, and even dementia far better than cholesterol, and most doctors never order them. In this episode, Robert Lufkin MD walks through fasting insulin + HOMA-IR, homocysteine, and high-sensitivity CRP — three tests that together cost about $60, take one blood draw, and catch the metabolic dysfunction a standard lipid panel systematically misses. CHAPTERS: 00:00 — The 3 Blood Tests Your Doctor Isn't Ordering 00:40 — Part 1: Fasting Insulin and HOMA-IR 01:15 — How Insulin Resistance Hides for 10–15 Years 01:45 — HOMA-IR vs Glucose: What 516,000 People Revealed 02:05 — 59% Higher Cardiovascular Risk in the 2023 ATVB Study 02:45 — Optimal Fasting Insulin: Why 5–8 Beats the Lab's "25" 03:05 — Part 2: Homocysteine and the MTHFR Connection 03:35 — How Homocysteine Damages Your Arteries (6 Mechanisms) 03:50 — 60% Higher Stroke Risk and 48% Alzheimer's Risk 04:35 — The Oxford VITACOG Trial: 53% Less Brain Atrophy 05:05 — Part 3: High-Sensitivity CRP and Inflammatory Plaque 05:40 — The JUPITER Trial: 44% Drop in Cardiac Events 06:15 — UK Biobank: Why hs-CRP Beats LDL Cholesterol 06:50 — AHA Risk Categories for hs-CRP Since 2003 07:15 — Part 4: The Metabolic Picture (Why Cholesterol Is the Wrong Target) 07:50 — 3 Tests, $60, One Blood Draw — The Full Framework KEY TAKEAWAYS: Fasting insulin + HOMA-IR catches insulin resistance a decade before glucose goes abnormal — optimal is below 5–8, not the lab's reference range of 25 Every 5 µmol/L rise in homocysteine raises coronary artery disease risk 20–30% and stroke risk 60%, independent of cholesterol hs-CRP predicted cardiovascular events better than LDL in a 322,000-person UK Biobank analysis — yet fewer than 10% of cardiac panels order it Cardiovascular disease, type 2 diabetes, and dementia share the same upstream driver: metabolic dysfunction, not cholesterol All three tests together cost roughly $60 and come from a single blood draw LINKS:

A new Alzheimer's blood test was just approved by the FDA and it changes everything about how families get answers. For years, confirming Alzheimer's disease meant expensive brain scans or invasive procedures most people couldn't access. Now a simple blood draw can detect Alzheimer's markers in the body... up to 3 to 4 years before symptoms even begin. In this episode I break down what the Alzheimer's blood test actually measures, how accurate it is, and what you can ask your doctor right now. If you'd like to see this episode on video, you can hop on over to my YouTube channel here. Get free weekly tools and tips in my newsletter, The Dementia Dose: https://tinyurl.com/dementiadose-podcast  CHAPTERS 00:00 You are not imagining this 01:18 Why an Alzheimer's diagnosis has always been so hard to get 03:30 What doctors were working with before 05:00 The new blood test: what it measures and how it works 07:15 How accurate is it? 08:30 What this means for you right now 11:00 What can still make this harder #dementia #dementiacare #alzheimers #dementiacaregiver --- Hi, I'm Dr. Natali Edmonds, a board-certified geropsychologist specializing in dementia care. Whether your loved one has Alzheimer's, frontotemporal, Lewy body, vascular, or mixed dementia, we believe that to create a dementia-friendly world, we must first create a caregiver-friendly world. This content is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for medical guidance.

In this episode, we explore a groundbreaking development in the diagnosis of chronic fatigue syndrome (CFS/ME) — a condition that affects millions worldwide, yet remains notoriously difficult to identify… Joining the podcast to discuss this topic are Alexandre Akoulitchev and Dmitry Pshezhetskiy, who break down a novel blood test designed to detect biological signatures associated with chronic fatigue. Their work centers on cutting-edge epigenetic science and biomarker discovery, offering new possibilities for more objective and earlier diagnosis of complex, hard-to-measure conditions. Hit play to discover: How a blood-based biomarker test may help identify chronic fatigue syndrome. The role of epigenetics in understanding complex, "invisible" illnesses. The four key symptoms of ME/CFS, and why it's so difficult to diagnose. How inflammation signals can contribute to chronic fatigue. Alexandre Akoulitchev is a molecular biologist specializing in genome regulation and chromatin architecture. He is a cofounder of Oxford BioDynamics and the creator of its EpiSwitch biomarker platform. He earned his PhD in cell biology from University College London. Dmitry Pshezhetskiy is a Professorial Research Fellow at Norwich Medical School and an academic clinician focused on cancer biology and therapeutic research. He completed his academic training at Moscow State University, Montréal institutions, and leading research centers in France, building a strong background in molecular medicine and translational research. You can connect with Alexandre Akoulitchev here and Dmitry Pshezhetskiy here!

A 96% accurate blood test for ME/CFS just dropped. And yes, it matters. But not for the reason you think. Today, I'll break down exactly what the new EpiSwitch test found, what it cannot tell you, and why no single lab result has ever been what actually gets people better. After a decade of working with long COVID and chronic fatigue syndrome patients, I've seen one consistent pattern: the people who recover are not the ones with the best test results. They're the ones who addressed all five root causes, no matter what the labs showed. In this episode, you'll learn: What the EpiSwitch test actually measures and why 96% accuracy is not the full story Why a negative result does not mean you are well What the "Toxic 5" are and why missing even one keeps people stuck How imperfect lab tests have fooled even experienced clinicians Why nervous system dysfunction is now confirmed in 57% of long COVID patients Discover your fatigue score and the root causes keeping you stuck: https://myfatiguescore.com Free Fatigue Masterclass: https://www.energymdmethod.com/masterclass-registration See real client results: https://energymdmethod.com/results Chapters: 00:00 - Introduction 00:28 - What Is the New ME/CFS Blood Test? 00:57 - How the EpiSwitch Platform Works 01:27 - Epigenetics Explained Simply 01:56 - The Helmholtz Center Study and the LCMO Cell 02:21 - Why This Validation Matters 02:50 - What the Headlines Are Leaving Out 03:19 - Why ME/CFS and Long COVID Are Not One Single Disease 03:48 - Evan's Personal Story and the Diagnosis Gap 04:46 - The Mold House Analogy 05:16 - CIRS and the Limits of Inflammatory Markers 05:46 - What Actually Drives Recovery: The Toxic Five 06:15 - Why Lab Tests Are Imperfect and What to Do About It 07:09 - Root Causes 11:53 - The Pattern Evan Has Seen in Every Recovery 12:23 - What the New Test Cannot Give You 12:51 - Celebrate the Science, But Don't Wait for It 13:43 - Three Things to Take Away from This Episode 14:40 - Free Masterclass Invitation 15:10 - Share This with Someone Who Needs It Subscribe to the EnergyMD Podcast for weekly conversations with leading experts on resolving ME/CFS and Long COVID by addressing the real root causes. . For more information about Evan and his program, Click Here.   Prefer to watch on Youtube? Click Here.   Please note that any information in this episode is for educational purposes only and does not constitute medical advice.

A recent study published in Nature Medicine claims a blood test can predict when you'll develop Alzheimer's disease, and it got a lot of attention. But how well does it actually work, and should you rush out and get tested? In this episode, we break down the study behind the headlines to understand what it really shows, where the major limitations lie, and what it means for anyone thinking about getting this kind of test. Topics and Questions Covered What P-Tau 217 is and why it's become the leading blood-based biomarker in Alzheimer's research. How researchers built a predictive "clock" from blood test data and what that process required. The important distinction between having pathology in your brain and actually developing dementia. Who should and should not be getting tested. What a large Norwegian population study reveals about the overlap between pathology and normal cognitive function. How biomarkers like this might eventually fit into a broader, more personalized approach to prevention. and more! -------------- To submit a question for us to answer on the podcast, go to brainjo.academy/question. To subscribe to the free Better Brain Fitness newsletter, join us when we record live, and get our Guide and Checklist to essential blood tests and nutrients, go to: betterbrain.fitness. To learn more about how you can boost brain fitness with neuroscience-based musical instruction, head to brainjo.academy.  Intro and Outro music composed and produced by Julienne Ellen. 

Kevin's blood test results are in and they're troubling...except for one area.

Most people think lab tests are only useful once something is wrong. But what if your blood work could show you where your health is headed—years before disease ever develops? In today's Office Hours, I break down how to read your labs through a functional medicine lens—so you can spot early dysfunction, connect the dots between symptoms and biomarkers, and take control of your health before problems escalate. In this episode, I walk you through: • Why “normal” lab ranges often miss early warning signs • The key markers that reveal the most about metabolic health, inflammation, thyroid function, nutrients, and cardiovascular risk • How functional medicine focuses on optimal ranges, patterns, and trends—not just disease thresholds • What your labs can tell you about symptoms like fatigue, brain fog, weight gain, and gut issues • How to track your numbers over time and ask smarter questions to shift from reaction to prevention Labs aren't just for diagnosing disease—they're a roadmap to optimizing your future health. When you understand your numbers, you stop guessing and start making data-driven decisions that build resilience and longevity. Visit ⁠functionhealth.com for 160+ lab tests at just $365 a year. Join the 10-Day Detox to Reset Your Brain and Metabolic Health https://drhyman.com/pages/10-day-detox Have a question you'd love answered on Office Hours? Submit it here